Psychedelics (primarily classic serotonergic agents like psilocybin/psilocin, LSD, and DMT/ayahuasca; with notes on MDMA) produce acute, dose-dependent, and substance-specific effects on brain electrical activity (EEG/MEG), cerebral blood flow (CBF), cardiac electrical activity (ECG), hemodynamics, and autonomic function. These are mediated mainly through 5-HT2A receptor agonism, leading to altered cortical excitability, network desynchronization, sympathomimetic activation, and neurovascular changes. Effects are typically transient (peaking 30–120 minutes post-dose and resolving within 4–12 hours), but they underpin both therapeutic potential (e.g., network “reset,” increased entropy) and risks (e.g., in contraindicated patients).
Data derive from controlled human studies (fMRI/ASL, EEG/MEG, PET), animal models, and reviews up to 2026. Quantitative values vary by dose, route (IV vs. oral), individual factors, and measurement method. Effects differ notably between substances (e.g., psilocybin vs. LSD on CBF).
Brain: Electrical Activity (EEG/MEG Oscillations and Connectivity)
Classic psychedelics induce broadband cortical desynchronization — a reduction in synchronized oscillatory power and network integrity, correlating with altered consciousness, ego dissolution, and perceptual changes.
- Spectral Power Changes (most consistent across psilocybin, LSD, DMT/ayahuasca):
- Decreased absolute power in low-to-mid frequencies: delta, theta (most studies), and especially alpha (8–13 Hz, often posterior/occipital; linked to relaxed wakefulness and top-down processing).
- Variable high-frequency effects: Often decreased or mixed in beta/gamma; some studies show increases in beta and gamma power with psilocybin.
- Example (recent double-blind study): Psilocybin (10–20 mg oral) significantly decreased theta and alpha power while increasing beta, gamma1, and gamma2 power vs. placebo. Subjective effects (Altered States of Consciousness Questionnaire) correlated with these EEG changes.105
- Systematic findings: Serotonergic psychedelics decrease alpha, beta, and delta power in healthy controls and MDD patients; gamma effects vary (decreases in healthy controls).106
- Animal (rat) data with psilocybin: Dose-dependent shifts in peak frequencies (e.g., decreased theta peak frequency at higher doses; increased medium/high gamma peak frequency initially).108
- Connectivity and Dynamics:
- Reduced functional connectivity (especially DMN hubs: posterior cingulate cortex/PCC and medial prefrontal cortex/mPFC).
- Increased signal diversity/entropy and “disintegration” of normal network segregation.
- Broadband decrease in coherence (cross-spectral and phase-lagged) across 0.5–40 Hz.
- These changes are more pronounced in association cortices and correlate with subjective intensity.
Mechanism: 5-HT2A-mediated excitation of deep-layer pyramidal neurons disrupts ongoing rhythms, leading to a state of higher entropy and reduced hierarchical control.
Clinical relevance: These electrical signatures support therapeutic “reset” effects but explain risks in psychosis-prone individuals (exacerbated desynchronization or instability).
Brain: Blood Flow and Neurovascular Coupling (fMRI, ASL, PET)
Psychedelics alter cerebral hemodynamics, often decoupling neuronal activity from blood flow/oxygenation (neurovascular uncoupling via serotonin effects on vessels). This complicates fMRI interpretation.
- Psilocybin:
- Decreases in global and regional CBF (arterial spin labeling/ASL and BOLD fMRI).
- Strongest reductions in connector hubs: thalamus, PCC, anterior cingulate (ACC), mPFC, and association cortices.
- Example: Significant CBF decreases correlating with subjective effects; one analysis noted ~12% global reduction in some contexts, with regional parietal/occipital effects.92
- Venous oxygenation and BOLD signal also often decrease.
- Neurovascular uncoupling: Blood flow responses to neuronal activity are altered/prolonged (e.g., extended capillary flow responses in visual cortex).
- LSD:
- Increases in global CBF (~19.3% mean increase; large effect size).
- Strongest in occipital/visual cortex (~26.4%) and thalamus (~19.4%); more modest in limbic areas (hippocampus ~15%, amygdala ~11%).
- Internal carotid artery (ICA) flow velocity increased ~28%; minimal change in ICA diameter.94
- Contrasts sharply with psilocybin’s decreases.
- General/Other:
- Increased glucose metabolism in some PET studies despite CBF changes.
- Visual cortex effects prominent (linked to hallucinations/imagery).
- fMRI shows disrupted resting-state connectivity and expanded primary visual cortex (V1) connectivity with LSD.
Mechanism: Direct vascular effects via serotonin receptors + indirect via altered neuronal demand. Recent work confirms psychedelics disrupt the normal neuron–blood flow linkage.
Heart: Electrical Activity (ECG) and Hemodynamics/Blood Flow
Effects are primarily autonomic (sympathomimetic) rather than direct myocardial toxicity in screened individuals.
- Electrical (ECG):
- Increased heart rate (HR; dose-dependent, transient peak in first 1–2 hours).
- Possible mild QTc prolongation (especially higher-dose psilocybin); theoretical torsades risk but rarely clinically significant in healthy volunteers.
- No consistent major increases in supraventricular/ventricular arrhythmias in controlled trials.
- Heart rate variability (HRV): Mixed; some reports of increased vagal tone or sympathovagal coactivation during peak experiences.104
- Hemodynamics and Blood Flow:
- Increased HR and blood pressure (BP; systolic and diastolic; typically 10–20+ mmHg rises, dose-dependent).
- Mediated via 5-HT2A/2B/4 receptor stimulation → sympathetic activation and direct cardiac effects (e.g., increased atrial contractility via 5-HT4).
- Transient cardiac workload increase; resolves within 6–12 hours.
- MDMA shows stronger stimulant-like pressor effects.
Safety note: These explain absolute contraindications in unstable CVD. Monitoring (continuous HR/BP, occasional ECG) is standard in trials.
Other Organs and Systemic Effects
- Autonomic Nervous System (ANS): Sympathovagal shifts — initial SNS increase (HR/BP, temperature fluctuations, pupil dilation); some evidence of increased vagal tone or coactivation during peak experiences. Correlates with subjective intensity (e.g., “spiritual experience,” insight). GI motility changes, nausea possible.113
- Neuroimmune/Vascular: Emerging data suggest anti-inflammatory effects (e.g., psilocybin/MDMA may reduce stress-induced monocyte accumulation in meninges/brain, potentially lowering neuroinflammation linked to fear/anxiety behaviors).
- Liver: Primary site of metabolism (psilocybin rapidly dephosphorylated to active psilocin via alkaline phosphatase; CYP enzymes involved). No major acute blood flow changes.
- Kidneys: Excretion of metabolites. Minimal direct hemodynamic effects.
- Other (lungs, endocrine, etc.): Minimal direct effects. Secondary changes possible via ANS (e.g., mild respiratory rate shifts, hormonal fluctuations). Peripheral vasoconstriction/vasodilation varies by substance/dose.
Overall Patterns and Variability:
- Dose- and substance-dependent: Lower doses milder; oral vs. IV differs in onset.
- Individual factors: Set/setting, genetics (e.g., 5-HT2A variants), concurrent meds, and baseline state modulate effects.
- Therapeutic implications: Electrical desynchronization + entropy increase + network flexibility may underlie rapid antidepressant/anti-anxiety effects. CBF changes and neurovascular shifts contribute to acute phenomenology.
- Risk context: These exact mechanisms underpin contraindications (e.g., psychosis risk from excessive desynchronization; CV events from pressor effects; seizure risk with lithium).
Welcome!